Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol®) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 5, 1998, Pages 400-406

  Souid, Abdul Kader ^a   Newton, Gerald L ^b   Dubowy, Ronald L ^a   Fahey, Robert C ^b   Bernstein, Mark L ^c  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Cancer therapy; Chemoprotection; Monobromobimane; Pediatric oncology; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BROMOBIMANE; CISPLATIN; DRUG METABOLITE; FLUORESCENT DYE;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; FEMALE; FLUOROMETRY; GERM CELL TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPOTENSION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL; SCHOOL CHILD; TECHNIQUE; VOMITING;

AMIFOSTINE; BICYCLO COMPOUNDS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORESCENT DYES; HALF-LIFE; HUMANS; MERCAPTOETHYLAMINES; PRODRUGS; RADIATION-PROTECTIVE AGENTS;

EID: 0031684655     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050836     Document Type: Article

References (32)

1. Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG (1995) A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 55: 4069
2. Amifostine (Ethyol®): current and future applications in cytoprotection (1996). Fur J Cancer 32A [Suppl 4]: S1-S49
3. Applications of Amifostine in cancer treatment (1996) Semin Oncol 23 [Suppl. 8]: 1-99
4. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23
5. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC (1988) Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634
6. Ellman GL (1959) Tissue sullfhydryl groups. Arch Biochem Biophys 82: 70
7. Fahey RC, Newton GL (1985) Measurement of WR-2721, WR-1065, and WR-33278 in plasma. Int J Radiat Oncol Biol Phys 11: 1193
8. Fahey RC, Newton GL (1987) Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. Methods Enzymol 143: 85
9. Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM (1986) WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase 11 trial. J Clin Oncol 4: 584
10. Glover D, Glick JH, Weiler C, Fox K, Guerry D (1987) WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574
11. Jocelyn PC (1987) Spectrophotometric assay of thiols. Methods Enzymol 143: 44
12. Korst AEC, Gall HE, Vermorken JB, van der Vijgh WJF (1996) Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 39: 162
13. Kosower NS, Kosower EM (1987) Thiol labeling with bromobimanes. Methods Enzymol 143: 76
14. Kosower NS, Kosower EM, Newton GL, Ranney HM (1979) Bimane fluorescent labels: labeling of normal human red cells under physiological conditions. Proc Natl Acad Sci USA 76: 3382
15. Mangold DJ, Huelle BK, Miller MA, Geary RS, Sanchez-Barona DOT, Swynnerton NF, Fleckenstein L, Ludden TM (1990) Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metab Dispos 18: 281
16. Mitchell JLA, Judd GG, Diveley RR, Choc CY, Leyser A (1995) Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis 16: 3063
17. Mollman JE, Glover DJ, Hogan WM, Furman RE (1988) Cisplatin neurotoxicity. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192
18. Newton GL, Fahey RC (1995) Determination of biothiols by bromobimane labeling and high-performance liquid chromatography. Methods Enzymol 251: 148
19. Newton GL, Aguilera JA, Kim T, Ward JF, Fahey RC (1996) Transport of aminothiol radioprotectors into mammalian cells: passive diffusion versus mediated uptake. Radiat Res 146: 206
20. Risley JM, Van Etten RL, Shaw LM, Bonner H (1986) Hydrolysis of S-2-(3-aminopropylamino)ethylphosphorothiolate. Biochem Pharmacol 35: 1453
21. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, Kligerman MM (1986) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501
22. Shaw LM, Bonner HS, Brown DQ (1994) Metabolic pathway of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 22: 895
23. Shaw LM, Bonner H, Lieberman R (1996) Pharmacokinetic profile of Amifostine. Semin Oncol 23 [Suppl 8]: 18
24. Shaw LM, Bonner HS, Schuchter L, Schiller JH, Nakashi MA, Lieberman R (1996) Population pharmacokinetics of amifostine in cancer patients. Proc Am Soc Clin Oncol 15: 478 (abstract 1515)
25. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF (1988) Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 48: 3641
26. Smoluk GD, Fahey RC, Ward JF (1988) Interaction of glutathione and other low-molecular-weight thiols with DNA: evidence for counterion condensation and coion depletion near DNA. Radiat Res 114: 3
27. Utley JF, Seaver N, Newton GL, Fahey RC (1984) Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 10: 1525
28. Yuhas JM (1979) Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 63: 971
29. Yuhas JM, Stoner JB (1969) Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42: 331
30. Yuhas JM, Spellman JM, Culo F (1980) The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211
31. Yuhas JM, Spellman JM, Jordan SW (1980) Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42: 574
32. Zheng S, Newton GL, Ward JF, Fahey RC (1992) Aerobic radioprotection of pBR322 by thiols: effect of thiol net charge upon scavenging of hydroxyl radicals and repair of DNA radicals. Radiat Res 130: 183